Dynavax Technologies Corp.
This article was originally published in Start Up
Executive Summary
Dynavax Technologies Corp. is developing vaccines to permanently alter immune system and inflammatory system responses. Its technology is based on proprietary artificial immunostimulatory DNA sequences, termed ISS, which act as a signal system and change the Th1/Th2 balance. In cases of allergies or asthma, the company's initial therapeutic focus, ISS administered with specific antigens drives the immune response from Th2 to Th1 to prevent initiation of the inflammatory process.
You may also be interested in...
In Vivo's Deals Of The Month, February 2018
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)
In Vivo's Deals Of The Month, January 2018
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)
In Vivo's 2017 Deals Of The Year: The Winners Are…
We nominated 15 deals in three categories. You picked the winners.